Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA.
Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, USA.
Ann Oncol. 2020 Oct;31(10):1386-1396. doi: 10.1016/j.annonc.2020.06.007. Epub 2020 Jun 17.
Patients with lung cancers may have disproportionately severe coronavirus disease 2019 (COVID-19) outcomes. Understanding the patient-specific and cancer-specific features that impact the severity of COVID-19 may inform optimal cancer care during this pandemic.
We examined consecutive patients with lung cancer and confirmed diagnosis of COVID-19 (n = 102) at a single center from 12 March 2020 to 6 May 2020. Thresholds of severity were defined a priori as hospitalization, intensive care unit/intubation/do not intubate ([ICU/intubation/DNI] a composite metric of severe disease), or death. Recovery was defined as >14 days from COVID-19 test and >3 days since symptom resolution. Human leukocyte antigen (HLA) alleles were inferred from MSK-IMPACT (n = 46) and compared with controls with lung cancer and no known non-COVID-19 (n = 5166).
COVID-19 was severe in patients with lung cancer (62% hospitalized, 25% died). Although severe, COVID-19 accounted for a minority of overall lung cancer deaths during the pandemic (11% overall). Determinants of COVID-19 severity were largely patient-specific features, including smoking status and chronic obstructive pulmonary disease [odds ratio for severe COVID-19 2.9, 95% confidence interval 1.07-9.44 comparing the median (23.5 pack-years) to never-smoker and 3.87, 95% confidence interval 1.35-9.68, respectively]. Cancer-specific features, including prior thoracic surgery/radiation and recent systemic therapies did not impact severity. Human leukocyte antigen supertypes were generally similar in mild or severe cases of COVID-19 compared with non-COVID-19 controls. Most patients recovered from COVID-19, including 25% patients initially requiring intubation. Among hospitalized patients, hydroxychloroquine did not improve COVID-19 outcomes.
COVID-19 is associated with high burden of severity in patients with lung cancer. Patient-specific features, rather than cancer-specific features or treatments, are the greatest determinants of severity.
患有肺癌的患者可能会出现不成比例的严重 2019 冠状病毒病(COVID-19)结局。了解影响 COVID-19 严重程度的患者特异性和癌症特异性特征,可能有助于在大流行期间为癌症患者提供最佳的治疗。
我们对 2020 年 3 月 12 日至 2020 年 5 月 6 日期间在一家单中心确诊患有肺癌和 COVID-19 的连续患者(n=102)进行了检查。预先定义了严重程度的阈值,住院、重症监护病房/插管/不插管(ICU/插管/DNI,严重疾病的综合指标)或死亡。康复定义为 COVID-19 检测后 >14 天且症状缓解后 >3 天。从 MSK-IMPACT(n=46)推断了人类白细胞抗原(HLA)等位基因,并与患有肺癌且无已知非 COVID-19 的对照组(n=5166)进行了比较。
肺癌患者的 COVID-19 较为严重(62%住院,25%死亡)。尽管病情严重,但 COVID-19 在大流行期间仅占肺癌总死亡人数的一小部分(总体为 11%)。COVID-19 严重程度的决定因素主要是患者的特定特征,包括吸烟状况和慢性阻塞性肺疾病[严重 COVID-19 的比值比(OR),与从不吸烟者相比,中位数(23.5 包年)为 2.9(95%置信区间(CI)为 1.07-9.44),与从未吸烟者相比为 3.87(95%CI 为 1.35-9.68)]。癌症特异性特征,包括先前的胸部手术/放疗和最近的全身治疗,并未影响严重程度。与非 COVID-19 对照组相比,COVID-19 轻症或重症患者的人类白细胞抗原超型通常相似。大多数患者从 COVID-19 中康复,包括 25%最初需要插管的患者。在住院患者中,羟氯喹并未改善 COVID-19 结局。
COVID-19 与肺癌患者的严重程度负担高有关。患者的特定特征,而不是癌症的特定特征或治疗方法,是严重程度的最大决定因素。